0001209191-20-037411.txt : 20200617
0001209191-20-037411.hdr.sgml : 20200617
20200617185152
ACCESSION NUMBER: 0001209191-20-037411
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200615
FILED AS OF DATE: 20200617
DATE AS OF CHANGE: 20200617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nicholson Garry A
CENTRAL INDEX KEY: 0001640861
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38871
FILM NUMBER: 20970858
MAIL ADDRESS:
STREET 1: C/O TESARO, INC.
STREET 2: 1000 WINTER STREET, SUITE 3300
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc.
CENTRAL INDEX KEY: 0001595893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463826166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-926-5251
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, Inc.
DATE OF NAME CHANGE: 20181018
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, INC
DATE OF NAME CHANGE: 20140106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-15
0
0001595893
Turning Point Therapeutics, Inc.
TPTX
0001640861
Nicholson Garry A
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DRIVE, STE. 200
SAN DIEGO
CA
92121
1
0
0
0
Stock Option (right to buy)
59.11
2020-06-15
4
D
0
25000
D
2030-01-21
Common Stock
25000
0
D
Stock Option (right to buy)
59.11
2020-06-15
4
A
0
23400
A
2030-01-21
Common Stock
23400
23400
D
The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.
/s/ Annette North, Attorney-in-Fact
2020-06-17